VA-REGULA
14.5.2024 09:01:37 CEST | Business Wire | Press release
MWC attracts tens of thousands of visitors, including representatives of mobile operators, device manufacturers, technology providers, vendors, and content owners. To ensure everyone's safety, the GSMA has traditionally conducted thorough registration and ID validation processes for each attendee.
For many years, the ID validation process was done on-site at the venue, which caused queues and long wait times. With the advent of the pandemic in 2020, and attendance now regularly exceeding 100,000, the GSMA had to find a contactless solution to remove the need to have attendees wait in large numbers to collect badges and have their ID validated. To address these issues and improve the efficiency of the registration process, the GSMA decided to make it totally remote and digital, so that all attendees could swiftly get access to the venue through the entry gates. Any solution would also need to enable quick and efficient international document recognition, because attendees come from all over the world.
To achieve their goal, the GSMA ran an extensive competitive tender process to find the best technology solution. Ultimately, they chose a complete, single-vendor solution by Regula which includes Regula Document Reader SDK and Regula Face SDK. Natively integrated, these solutions facilitate a smooth customer journey and rapid onboarding through seamless and secure identity verification, eliminating the possibility of fraud.
Having successfully piloted Regula products during MWC Barcelona 2021, the GSMA fully transitioned to digital visitor registration and ID validation. After several years of collaboration, this long-term partnership led to a significant enhancement of the visitor registration process, enabling a fast and convenient user experience. Now, Regula Document Reader SDK and Regula Face SDK are easily integrated into the MWC’s existing registration platform for full-fledged production use.
Now, as part of the registration process, an MWC visitor simply uploads their ID on the official website. The identity document is automatically scanned by Regula Document Reader SDK. The solution instantly recognizes the document type, reads its data, and verifies its authenticity with multiple cross-checks. Not only does it streamline the verification process (checks are completed in seconds), but it also minimizes the chance of missing compromised IDs.
Further, an MWC attendee has the opportunity to provide their selfie, which is rapidly captured by Regula Face SDK for user verification.
With the industry’s largest and most comprehensive identity document template database, which contains over 13,600 templates from 249 countries and territories, Regula supports the verification of nearly any identity document from any part of the world. Taking into account MWC attendees’ geographical spread, this ability significantly facilitates the registration process.
With Regula’s complete IDV solution, the GSMA managed to create a custom, smooth, and seamless registration experience for all MWC attendees. During the Barcelona event in 2024, Regula solutions helped to efficiently validate more than 100,000 visitors – all of them registered online beforehand, so there was no need to queue at the venue.
"Our collaboration with GSMA for MWC highlights the power of digital transformation in handling large-scale international events. By integrating our advanced ID verification technologies, not only did we enhance the security and efficiency of the registration process, but also ensured a seamless experience for attendees," says Ihar Kliashchou, Chief Technology Officer at Regula.
“The digital identity verification process has revolutionized the visitor experience, allowing more than 100,000 individuals to register and access the world’s leading connectivity event swiftly, safely, and without interruption," states Xavi Casals, Director of Technology, Innovation & Customer Experience at GSMA.
For more details on the business case, please visit the Regula website.
About GSMA
The GSMA is a global organisation unifying the mobile ecosystem to discover, develop and deliver innovation foundational to positive business environments and societal change. Our vision is to unlock the full power of connectivity so that people, industry and society thrive. Representing mobile operators and organisations across the mobile ecosystem and adjacent industries, the GSMA delivers for its members across three broad pillars: Connectivity for Good, Industry Solutions and Events.
Find out more at gsma.com.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514134027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
